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Changes in the expression of the melanin concentrating hormone receptor 1 (MCHR1) are involved in a
variety of pathologies, especially obesity and anxiety disorders. To monitor these pathologies in-vivo pos-
itron emission tomography (PET) is a suitable method. After the successful radiosynthesis of [11C]SNAP-
7941—the ﬁrst PET-Tracer for the MCHR1, we aimed to synthesize its [18F]ﬂuoroethylated analogue:
[18F]FE@SNAP. Therefore, microﬂuidic and vessel-based approaches were tested. [18F]ﬂuoroethylation
was conducted via various [18F]ﬂuoroalkylated synthons and direct [18F]ﬂuorination. Only the direct
[18F]ﬂuorination of a tosylated precursor using a ﬂow-through microreactor was successful, affording
[18F]FE@SNAP in 44.3 ± 2.6%.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Melanin concentrating hormone (MCH) is a cyclic neuropeptide
originally isolated from the salmon pituitary gland as a hormone
responsible for skin pigmentation in teleost ﬁsh.1 In mammals,
MCH is predominantly expressed in the lateral hypothalamus
and zona incerta,2,3 but is also found in peripheral organs and tis-
sues, such as the pancreas,4 colonic epithelial cells5 or adipo-
cytes.6,7 It plays a key role in energy homeostasis, e.g. the control
of food intake, body weight and metabolism.8,9 Furthermore, it is
involved in anxiety,10–14 diabetes,4 gut inﬂammation5 and adipos-
ity.6,7 The biological function of MCH is mediated by two G-protein
coupled receptors, MCH receptor 1 and 2 (MCHR115–18 and
MCHR2.19–22) The widespread distribution of MCH and its recep-
tors and the involvement in a variety of pathologies makes the
MCH system interesting as a target to treat human disorders.x: +43 1 40400 1559.
.at (W. Wadsak).
ipt.
-NC-ND license.Several MCHR1 antagonists were presented in the last decade;
some of them have entered clinical trials for the treatment of obes-
ity,23 some are in discussion of becoming anti-diabetic drugs.24
However, to enable conﬁdence in preclinical to clinical translation
of central MCHR1 pharmacology, a suitable positron emission
tomography (PET) tracer needs to be developed. Borowsky et al.25




hydrochloride, 1, Figure 1) (Kd = 0.18 nM, evaluated on Cos-7 cells
expressing the human MCHR1 (hMCHR1)).25 We previously re-
ported the successful radiosynthesis of its radiolabelled analogue,
[11C]SNAP-7941—the ﬁrst PET tracer for the MCHR1.26 Due to the
practical advantages of the longer-lived radioisotope 18F (t1/
2 = 110 min) instead of 11C (t1/2 = 20 min) and the comparable sta-
bility of methyl- and ﬂuoroethylesters,27 we aimed to synthesize
a [18F]ﬂuoroethylated analogue: [18F]FE@SNAP (2, Fig. 1). We per-
formed preliminary stability tests by incubation in human plasma
at 37 C which showed almost no degradation (<5%) within























Figure 1. SNAP-7941 derivatives 1–4 (1: SNAP-7941; 2: [18F]FE@SNAP; 3: SNAP-
acid; 4: Tos@SNAP).
C. Philippe et al. / Bioorg. Med. Chem. 20 (2012) 5936–5940 5937revealed only 20% cleavage within 6 h. Additionally, in preliminary
binding experiments on CHO-hMCHR1 cell membranes, FE@SNAP
evinced similar binding afﬁnity as the parent compound SNAP-
7941 (Kd = 0.18 nM).
In general, 18F-ﬂuoroalkyl radiolabels can be introduced using
either a direct [18F]ﬂuorination of a suitable precursor-compound
(already containing a leaving group at the alkyl side chain) or via
two step labelling reaction using an 18F-ﬂuoroalkylating synthon.
Even for ﬂow-through microreactor procedures both synthesis
strategies have already been reported for various radiotracer syn-
theses: For example, direct radio-ﬂuorinations were presented
for 2-[18F]FDG,28–31 [18F]fallypride,32 [18F]annexin,29,31 and N-
[18F]ﬂuoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline;33
furthermore, the [18F]ﬂuoroethylation of carboxylic acids,34
[18F]ﬂuoroalkylation of diverse [18F]ﬂuorocholine derivatives using
either [18F]ﬂuoroethyl tosylate or [18F]ﬂuoropropyl tosylate35,36
and the syntheses of [18F]ﬂuoroarenes from diaryliodonium salts37
have been presented.
The aim of this work was the preparation of [18F]FE@SNAP in
sufﬁcient amounts for future pre-clinical applications. For this pur-
pose, vessel-based as well as microﬂuidic approaches were con-
ducted, starting from two different precursors: SNAP-acid (3,
Fig. 1) (for the two step [18F]ﬂuoroalkylation) and Tos@SNAP (4,
Fig. 1) (for direct radiolabelling).
2. Results and discussion
2.1. General
TLC Rf-values were 0.00–0.02 for [18F]ﬂuoride and 0.63–0.69 for
[18F]FE@SNAP. A typical radio-TLC sample chromatogram isFigure 2. Typical radio-TCL chromatogram of the crude reaction mixtupresented in Figure 2. HPLC retention times were 2.3–2.6 min
(k0 = 0.5–0.7) for Tos@SNAP and 5.1–5.9 min (k0 = 2.4–2.9) for
[18F]FE@SNAP. All values were veriﬁed by inactive reference sub-
stances. The TLC Rf-values of the two additional, unknown radio-la-
belled side products were 0.76–0.82 and 0.87–0.93, ‘respectively’;
HPLC retention times were 3.6–4.3 min (k0 = 1.4–1.7) and 6.9–
7.7 min (k0 = 3.6–4.1).
2.2. Vessel-based preparation
The production of all [18F]ﬂuoroalkylation agents ([18F]BFE,
[18F]FEtTos, [18F]FEtTf) was successful: 2.9 ± 0.9 GBq [18F]BFE
(23.1 ± 10.4% EOB), 0.3 ± 0.1 GBq [18F]FEtTos (24.0 ± 0.7% EOB)
and 0.3 ± 0.2 GBq [18F]FEtTf (19.2 ± 9.6% EOB) were achieved. How-
ever, the [18F]ﬂuoroethylation of SNAP-acid via these synthons did
not succeed. No radiochemical incorporation was observed regard-
less of the conditions applied (reaction temperature, reaction time,
solvent, synthon). Furthermore, the direct ﬂuorination of Tos@
SNAP in the conventional approach was not successful, either.
Again, no radiochemical incorporation was observed.
2.3. Microﬂuidic preparation
Radiolabelling of the [18F]ﬂuoroalkylation agent [18F]FEtTos was
in accordance to the literature.35,36 However, the second step—the
[18F]ﬂuoroethylation of SNAP-acid—was not successful using this
approach.
The direct [18F]ﬂuorination via the microﬂuidic system ﬁnally
resulted in the production of [18F]FE@SNAP. The RCIY was increas-
ing with higher reaction temperatures and increasing amounts of
precursor. Highest RCIYs were obtained at 170 C using 4 mg/mL
of precursor in the reaction mixture (43.8 ± 2.2%). Further raise of
precursor amount did not improve synthetic outcome (Fig. 3). Rea-
sonable radiolabelling yields and no formation of any side products
could be observed at 100 C. At 140 C radiochemical incorporation
was increased but two unknown radiolabelled side products were
formed additionally. When increasing the reaction temperature up
to 170 C side product formation was even more pronounced. At
the same time degradation of precursor with increasing tempera-
ture could be observed in the UV channel of the HPLC chromato-
gram. This degradation also increased with slow ﬂow rates.
Therefore, the dependency upon the ﬂow rate was determinedre (7.5 mg/mL, 170 C, 150 lL/min) with results after integration.
Figure 3. Dependency of the RCIY upon precursor concentration. Reactions were
performed with a ﬂow rate of 60 lL/min at 100 C, 140 C and 170 C. Values are
decay-corrected and given as arithmetic means ± SD (nP 3). Error bars are depicted
unidirectional for better visualization but represent deviations in both directions.
Table 1
Optimum reaction conditions and outcome for the preparation of [18F]FE@SNAP
Amount of precursor (mg/mL) 4
Reaction temperature (C) 170
Flow rate (lL/min) 150
RCIY (%) 43.8 ± 2.2
5938 C. Philippe et al. / Bioorg. Med. Chem. 20 (2012) 5936–5940both at 140 C and 170 C (7.5 mg/mL Tos@SNAP, Fig. 4). At 170 C
the RCIY increased with increasing ﬂow rates. The inverse trend
was observed at 140 C. RCIYs decreased with increasing ﬂow
rates. However, best RCIYs were observed using fast ﬂow rates
up to 150 lL/min at 170 C. In this set-up the residence time with-
in the heated microreactor (15.6 lL) was only 6.24 s. This time was
sufﬁcient to radiolabel the tosylated precursor and short enough to
avoid extensive precursor degradation. RCIY of [18F]FE@SNAP was
increased from 25.1 ± 1.8% (20 lL/min) to 44.3 ± 2.6% (150 lL/
min) applying 7.5 mg/mL precursor at 170 C.
Due to previous ﬁndings, 38 the reaction volume was examined
as additional parameter. No ‘‘bolus volume effect’’ could be ob-
served for this set-up. For reactions using 3 mg/mL Tos@SNAP at
170 C and a ﬂow rate of 150 lL/min, RCIY was similar for small-
scale reactions (20 lL) and for enlarged reaction boluses
(300 lL): 30.5 ± 8.9%.
All these results led to the optimum reaction conditions for the
radiochemical preparation of [18F]FE@SNAP summarized in
Table 1.
3. Conclusion
[18F]FE@SNAP could not be synthesized in any vessel-based
approach neither using direct radio-ﬂuorination of the tosylated
precursor nor through the coupling of a [18F]ﬂuoroalkylation agentFigure 4. Inﬂuence of the overall ﬂow rate on the RCIY. Reactions were conducted
using 7.5 mg/mL Tos@SNAP in reaction mixture. Values are decay-corrected and
given as arithmetic means ± SD (nP 3).to SNAP-acid. Once again, ﬂow-through microreactor technology
was demonstrated to be a valuable addition in the portfolio of
radiolabelling techniques for the preparation of new PET tracers.
Solely, a microﬂuidic procedure enabled the radiosynthesis of
[18F]FE@SNAP. Further experiments comprising an up-scaling,




Chemicals and solvents were purchased from Merck (Darms-
tadt, Germany) and Sigma-Aldrich (Vienna, Austria). All reagents
were at least of analytical grade and used without puriﬁcation.
[18F]ﬂuoride was produced via the 18O(p,n)18F reaction in a GE PET-
trace cyclotron (16.5-MeV protons; GE Medical Systems, Uppsala,
Sweden). H218O (HYOX18; >98%) was purchased from Rotem Eur-
ope (Leipzig, Germany). Anion-exchange cartridges (PS-HCO3) for
[18F]ﬂuoride trapping were obtained from Macherey-Nagel (Duer-
en, Germany). 2-bromoethyl triﬂate39 (BETfO) and ethylene glycol
bis triﬂate40 were synthesized in cooperation with the Department
of Drug and Natural Product Synthesis of the University of Vienna
(Austria). Alumina cartridges (Sep-Pak Light Alum N) were pur-
chased from Waters (Waters Associates Milford, MA, USA). For
conventional small-scale preparations, the reactions were carried
out in Wheaton 1.0 mL v-vials (clear glass) assembled with TFE/sil-
icone septa. Microﬂuidic reactions were carried out within an Adv-
ion NanoTek unit (Ithaca, NY, USA) comprising a concentrator
unit (CE) and a liquid ﬂow reaction unit (LF) with dedicated control
software (Advion, version 1.4). The set-up is illustrated in Figure 5.
Microreactors were made of fused silica tubing (inner diameter
0.1 lm; length 2.0 m), wound-up and held in a brass ring ﬁlled
with a thermoresistant polymer to hold the tubing in its place. Dry-
ing and collecting v-vials (3.0 and 5.0 mL, clear glass) were ob-
tained from Alltech (Deerﬁeld, IL, USA). Radiochemical
incorporation yields (RCIYs) were determined by analysing the
reaction mixtures by radio-analytical thin-layer chromatography
(radio-TLC) and analytical high performance liquid chromatogra-
phy (HPLC). Radio-TLC was performed using silica gel 60 RP-18
F254S plates fromMerck (Darmstadt, Germany) (mobile phase: ace-
tonitrile/water 95/5 v/v). Analyses of radio-TLC plates were done
using a Canberra-Packard Instant Imager (Perkin Elmer, Watford,
UK). Analytical HPLC was performed using an Agilent system
(Boeblingen, Germany) consisting of an autosampler 1100, a qua-
ternary pump 1200 (ﬂow: 1 mL/min), a diode array detector
1200 (operated at 255 nm) and a lead-shielded NaI-radiodedector
(Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany).
HPLC column (Chromolith Performance RP-18e; 100–4.6 mm)
was purchased from Merck (Darmstadt, Germany). HPLC mobile
phase consisted of (water/acetic acid 97.5/2.5 v/v; 2.5 g/L ammo-
nium acetate; pH 3.5)/acetonitrile 70/30 v/v.
4.2. Preparation of precursor compounds and reference
standard
Syntheses of precursor compounds (SNAP-acid26 and Tos@
SNAP41,42) and reference standard (FE@SNAP43) were performed
Figure 5. Schematic illustration of the set-up of the Advion NanoTek system for two-step reactions.
C. Philippe et al. / Bioorg. Med. Chem. 20 (2012) 5936–5940 5939in cooperation with the Department of Drug and Natural Product
Synthesis of the University of Vienna (Austria). 1H- and 13C-NMR
data and spectra as well as 19F-NMR, MS, HRMS and IR data, are
available as Supplementary data.
4.3. Azeotropic drying
Azeotropic drying of cyclotron produced [18F]ﬂuoride was
always performed within the concentrator unit of the Advion
NanoTek synthesizer using a programmed procedure, in order
to avoid differences between manual and automatic azeotropic
drying. N.C.A [18F]ﬂuoride (1.5–31.7 GBq) was trapped on to an
anion exchange cartridge (PS-HCO3) and released with a solution
containing Kryptoﬁx 2.2.2 (4,7,13,16,21,24-hexaoxa-1,10-diaza-
bi-cyclo[8.8.8]hexacosane; 10 mg, 26.6 lmol) and potassium
carbonate (2.25 mg, 16.6 lmol) in acetontrile/water (70/30 v/v;
V = 0.5 mL). Iterative azeotropic drying was performed at 110 C
by addition of 3 times 300 lL of dry acetonitrile.
4.4. Vessel-based preparation
4.4.1. Fluoroethylation via 1-bromo-2 [18F]ﬂuoroethane
([18F]BFE)
[18F]BFE was produced according to Zuhayra et al.44 Brieﬂy, to
the dried [18F]ﬂuoride-aminopolyether a mixture of 30 lL BETfO
and 500 lL 1,2-dichlorobenzene (o-DCB) was added. After heating
at 100 C for 10 min, [18F]BFE was distilled at 130 C under helium
ﬂow into the respective solvent (DMF, DMSO and 2-butanone). The
precursor SNAP-acid (4 mg/mL) was activated by adding an equi-
molar amount of tetrabutylammonium hydroxide (TBAH) and dis-
solved in the respective solvent. The [18F]BFE solution was added
to the precursor solution (1:1) and the reaction mixture was
heated at 75–140 C for 10–20 min.
4.4.2. Fluoroethylation via [18F]ﬂuoroethyl tosylate
([18F]FEtTos)
Ethylene glycol di-P-tosylate (9.25 mg/mL in acetonitrile) was
added to the dried [18F]ﬂuoride-aminopolyether and heated at85 C for 15 min. The resulted [18F]FEtTos was added to SNAP-acid
(activated with TBAH, 4 mg/mL in acetonitrile) (1:1) and the reac-
tion mixture was heated at 75 C for 10–30 min.
4.4.3. Fluoroethylation via [18F]ﬂuoroethyl triﬂate ([18F]FEtTf)
[18F]FEtTf was produced according to Kiesewetter et al.40
Brieﬂy, a solution of ethylene glycol bis triﬂate (1.0 mg in 100 lL
acetonitrile) was added to the dried [18F]ﬂuoride-aminopolyether.
After heating at 125 C for 1 min, the solution was cooled in an ice
bath and triﬂic anhydride (5 lL) was added. The solution was
loaded onto an alumina cartridge and [18F]FEtTf was eluted with
acetonitrile (500 lL). The solution of [18F]FEtTf was added to
SNAP-acid (activated with TBAH, 4 mg/mL in acetonitrile) (1:1)
and heated at 75 C for 10–30 min.
4.4.4. Direct [18F]ﬂuorination
The tosylated precursor Tos@SNAP (2 mg/mL) was dissolved in
acetonitrile and added to the dried [18F]ﬂuoride-aminopolyether.
The reaction mixture was heated at 75 C for 10–90 min.
4.5. Microﬂuidic preparation
4.5.1. Fluoroethylation via [18F]ﬂuoroethyl tosylate
([18F]FEtTos)
Reaction educts were dissolved in acetonitrile and drawn into
the respective loops (loop 1: ethylene glycol di-P-tosylate (10 mg/
mL); loop 2: SNAP-acid (activated with TBAH, 20 mg/mL); loop 3:
dried [18F]ﬂuoride-aminopolyether in 500 lL acetonitrile). Before
starting the experiments, transfer-lines were ﬁlled with the solu-
tions from the storage loops and the reactors were ﬁnally swept
with the reaction solvent via pump 3 (Fig. 2). The synthesis was
carried out within the Advion NanoTek using the ‘discovery
mode’ for two step reactions. The conversion to [18F]FEtTos (ﬁrst
reaction) was performed by pushing the previously ﬁlled solutions
simultaneously from loop 1 and 3 through the ﬁrst temperature
controlled (180 C) ﬂow-through microreactor (ﬂow rate: 30–
50 lL/min). In a second phase the [18F]FEtTos-mixture was swept
out of the reactor through the storage line towards the other
5940 C. Philippe et al. / Bioorg. Med. Chem. 20 (2012) 5936–5940reactor. The second reaction starts when the [18F]FEtTos-mixture
and the precursor solution (loop 2) are pushed through the second
microreactor (100–180 C) with deﬁned velocity (20–150 lL/min)
followed by a ﬁnal sweeping where the reaction mixture is ﬁnally
ﬂushed out of the system into a collecting vial ﬁlled with 200 lL of
solvent. Total reaction bolus volumes between 28 lL and 90 lL
(7 + 7 + 14 and 15 + 15 + 60 lL) were tested.
4.5.2. Direct [18F]ﬂuorination
Dried [18F]ﬂuoride-aminopolyether dissolved in 500 lL acetoni-
trile and Tos@SNAP (3–10 mg/mL in acetonitrile) precursor solu-
tion were drawn and stored in the respective loops of pumps 1
and 3 of the LF unit. Before starting the experiments, transfer lines
1 and 3 were ﬁlled with the solutions from the storage loops and
the reactor was swept with the reaction solvent via pump 3. Opti-
mal reaction conditions were determined using the pre-installed
‘discovery’ mode for one step reactions: small volumes (5–
200 lL) of the previously ﬁlled solutions were simultaneously
pushed through the temperature-controlled reactor (100–200 C)
with deﬁned overall ﬂow rates (60–150 lL/min). Subsequently,
the crude product solution was swept out of the micro reactor with
a deﬁned volume of 200 lL of acetonitrile into collection vials.
4.6. Statistical analyses
Quantitative data (both in text and ﬁgures) are expressed as
arithmetic mean ± standard deviation. If not stated otherwise all
experiments were performed in triplicates.
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